Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Klin Khir ; (6): 31-5, 1999.
Article in Russian | MEDLINE | ID: mdl-10483186

ABSTRACT

The data about the ability of various substances to cause definite reactions in biological objects are adduced, and, in particular, about the efficacy of a small doses of antitumoral chemopreparations in experiment. The results of investigation of the application efficacy of various doses of immunomodulating agents, such as arbisol, nucleoplat, the substrate from gram-negative bacteria Yersinia enterocolitica, antitumoral vaccine from the tumoral cells are presented for the cancer chemotherapy. While application of super-small doses of an antitumoral vaccine there was noted statistically significant inhibition of tumoral growth.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Biological Factors/administration & dosage , Cancer Vaccines/administration & dosage , Cisplatin/administration & dosage , DNA Adducts/administration & dosage , Neoplasms, Experimental/drug therapy , Animals , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Female , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Neoplasm Transplantation , Time Factors , Yersinia enterocolitica
4.
Lik Sprava ; (11-12): 114-7, 1992.
Article in Russian | MEDLINE | ID: mdl-1292205

ABSTRACT

The authors studied the antitumour activity of a new complex platinum compound (DDP-DNA) in mice with leukemia P-388 and in cell culture. DDP-DNA was introduced intraperitoneally 24 hours after inoculation of 2 x 10(6) tumour cells. It was established that by its antitumour activity DDP-DNA was not inferior then DDP. The antiproliferative activity of nontoxic doses of the preparation in cell culture has been shown.


Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/therapeutic use , DNA Adducts , DNA/therapeutic use , Leukemia P388/drug therapy , Animals , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Mice , Mice, Inbred DBA , Neoplasm Transplantation , Time Factors , Tumor Cells, Cultured/drug effects
5.
Klin Khir (1962) ; (1): 40-1, 1992.
Article in Russian | MEDLINE | ID: mdl-1564866

ABSTRACT

Results of the use of polyplatillen--a preparation consisting of sodium nucleinate (deoxyribonucleic acid) and cisplatin combined in the saline balanced solution by means of the original technique--in cancer of the ovaries (198 patients), liver (62), pancreas (35), lungs (12), stomach (5) are presented. Clearly pronounced specific activity of the preparation developed is noted.


Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/administration & dosage , Cisplatin/therapeutic use , Digestive System Neoplasms/drug therapy , Lung Neoplasms/drug therapy , Nucleic Acids/administration & dosage , Ovarian Neoplasms/drug therapy , Digestive System Neoplasms/mortality , Digestive System Neoplasms/pathology , Drug Combinations , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Neoplasm Staging , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Remission Induction , Time Factors
6.
Klin Khir (1962) ; (6): 15-7, 1992.
Article in Russian | MEDLINE | ID: mdl-1453616

ABSTRACT

Toxic action of polyplatillen, a principally new platinum compound, was studied on laboratory animals and cell culture. When compared with cis-dichlorodiamminplatinum, the preparation is 10-fold less toxic in animals and 100-fold--in the cellular systems. Reversibility of damaging action of polyplatillen at "non-toxic" dosages conditions the perspectiveness of its further clinical trials.


Subject(s)
Cisplatin/toxicity , Animals , Cells, Cultured , Cisplatin/administration & dosage , Dogs , Mice , Rats
SELECTION OF CITATIONS
SEARCH DETAIL